文献速递心脏核医学

心脏正电子发射断层扫描及其他冠状动脉疾病评估模式:来自医疗保险数据的快照

Cardiac positron emission tomography and other modalities for coronary artery disease assessment: A snapshot from the medicare data.
PubMed 文献 · J Nucl Cardiol · 2024-09-02

该研究利用医疗保险数据比较了2018至2022年心脏PET与其他冠状动脉疾病评估模式的使用频率及解读医师情况。2022年PET心肌灌注显像计费212,106例,SPECT为1,343,519例,约为PET的六倍;PET扫描中46%为PET/CT,39%包含心肌血流量测定。2018至2022年PET、CT和MRI使用增加,而SPECT和负荷超声心动图下降。

要点

  • 2022年医疗保险计费PET心肌灌注显像212,106例,SPECT 1,343,519例,SPECT约为PET的六倍。
  • PET心肌灌注显像中46%为PET/CT,39%包含心肌血流量测定。
  • 86%的PET扫描由心脏科医师解读,每位解读医师中位数为58项检查,23%的医师年解读量≤25项。

核心结论

  • 在医疗保险人群中,放射性核素灌注显像(SPECT和PET)仍是冠状动脉疾病评估的首选方法,SPECT是最常用的模式,PET是第二常用的模式。
  • PET/CT和心肌血流量测定未得到充分利用,限制了诊断和预后能力。
  • 需要努力加强教育和提高对PET优势的认识,并解决其更广泛应用的障碍,以最大化其临床获益并改善患者结局。

研究设计与样本

  • 利用医疗保险数据,比较心脏PET手术计费数量与SPECT、冠状动脉CT血管造影(CCTA)、负荷磁共振成像(MRI)和负荷超声心动图。
  • 使用医疗保健通用操作编码系统代码识别手术,计算PET心肌灌注显像手术总数、PET/CT和心肌血流量评估的比例以及每位医师解读检查的中位数。
  • 分析2018年至2022年不同冠状动脉疾病评估模式的使用趋势,采用描述性统计总结数据。

主要发现

  • 2022年医疗保险计费PET心肌灌注显像212,106例;SPECT为1,343,519例,约为PET的六倍;负荷超声心动图201,676例,CCTA 118,734例,使用相似或更低;负荷MRI 3,932例,使用最少。
  • PET心肌灌注显像中46%为PET/CT,39%包含心肌血流量测定。
  • 86%的PET扫描由心脏科医师解读,每位解读医师中位数为58项检查;23%的医师年解读量≤25项。
  • SPECT每位解读医师中位数为63项检查;CCTA、负荷MRI和负荷超声心动图的中位数分别为27、20和24项。
  • 2018年至2022年PET、CT和MRI使用增加,而SPECT和负荷超声心动图下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Positron emission tomography (PET) is an important tool for assessing coronary artery disease (CAD), but its widespread utilization is limited due to various factors, including limited local champion availability. This study aims to compare the frequency of PET procedures and their interpreters with other common CAD assessment modalities. METHODS: Using Medicare data, we examined the number of cardiac PET procedures billed and compared them with single-photon emission computed tomography (SPECT), coronary computed tomography angiography (CCTA), stress magnetic resonance imaging (MRI), and stress echocardiography. Healthcare Common Procedure Coding System codes were used to identify procedures. We calculated the total number of PET myocardial perfusion imaging (MPI) procedures, the proportion of PET/CT and myocardial blood flow (MBF) assessments, and the median number of studies read per physician. We also analyzed the trends in the use of different CAD assessment modalities between 2018 and 2022. Descriptive statistics summarized the data. RESULTS: In 2022, Medicare billed for 212,106 PET MPI scans. SPECT was six times more frequent (1,343,519), whereas stress echocardiography (201,676) and CCTA (118,734) had similar or lower use. Stress MRI (3,932) was least used. Of the PET MPI scans, 46% were PET/CT, and 39% included MBF measurements. Cardiologists interpreted 86% of PET scans, with a median of 58 studies per reader; 23% interpreted ≤25 studies annually. SPECT had a median of 63 studies per reader, and CCTA, stress MRI, and stress echocardiography had medians of 27, 20, and 24, respectively. PET, CT, and MRI use increased from 2018 to 2022, whereas SPECT and stress echocardiography declined. CONCLUSION: In the Medicare population, radionuclide perfusion imaging (SPECT and PET) remained the preferred method for assessment of CAD, with SPECT being the most frequently used modality and PET being the second most frequently used modality for this application. However, PET/CT and MBF are underutilized, limiting diagnostic and prognostic capabilities. Efforts to enhance education and awareness of PET's advantages and to address barriers to its wider adoption are essential to maximize its clinical benefits and improve patient outcomes.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Al-Mallah M, Alwan M, Al Rifai M, et al. Cardiac positron emission tomography and other modalities for coronary artery disease assessment: A snapshot from the medicare data. J Nucl Cardiol. 2024. PMID: 39233112. doi:10.1016/j.nuclcard.2024.102030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。